<DOC>
	<DOCNO>NCT00384033</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy safety two dos DVS SR ( 50 100 mg/day ) treatment adult Major Depressive Disorder .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release ( DVS SR ) In The Treatment Of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>A primary diagnosis Major Depressive Disorder , single recurrent episode , without psychotic feature . Depressive symptoms least 30 day screen visit . Outpatient men woman least 18 year age . Significant risk suicide base clinical judgment , include common suicidal thought suicide consider possible solution even without specific plan intent . Any unstable hepatic , renal , pulmonary , cardiovascular ( include uncontrolled hypertension ) , ophthalmologic , neurologic , medical condition might confound study put subject great risk study participation . Current ( within 12 month baseline ) psychoactive substance abuse dependence ( include alcohol ) , manic episode , posttraumatic stress disorder , obsessivecompulsive disorder , lifetime diagnosis bipolar psychotic disorder ; b ) current ( within 12 month baseline ) generalize anxiety disorder , panic disorder , social anxiety disorder ; c ) presence ( within 12 month baseline ) clinically important personality disorder assess psychiatric assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>MDD</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>